Exhibit 99.1
Eagle Pharmaceuticals December 2019 © 2019 Eagle Pharmaceuticals, Inc. All rights reserved Innovation in Pharmaceuticals: Transforming Patient Care by Targeting Best - in - Class Solutions
2 Forward Looking Statements This presentation contains forward - looking information within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, and other securities laws . Forward - looking statements are statements that are not historical facts . Words such as “will,” “underway,” “allow,” “expect( ed ),” “pursuing,” “may,” “would,” “addressing,” “creating,” “intends,” “anticipate(s),” “plan,” “partner,” “could,” “enables,” “potential( ly ),” and similar expressions are intended to identify forward - looking statements . These statements include, but are not limited to, statements regarding future events such as : the outcome of the review by the U . S . Department of Justice and the Federal Trade Commission of the settlement agreement with Eli Lilly with respect to PEMFEXY ; anticipated timing of final approval of the PEMFEXY NDA by the U . S . Food and Drug Administration, if at all ; the timing of Eagle's PEMFEXY launch ; the success, if any, of Eagle's marketing and sales efforts regarding PEMFEXY ; the continued commercial performance of our marketed products, including but not limited to Bendeka , which is marketed by our partner Teva , RYANODEX, which we market ourselves, as well as our ability to replicate our marketing successes for our other product candidates such as RYANODEX for Exertional Heat Stroke (EHS) or other additional indications, our pemetrexed candidate, or our fulvestrant candidate, either through joint or direct marketing efforts ; Eagle's ability to advance RYANODEX in the treatment of Acute Radiation Syndrome (ARS) and organophosphate (nerve agent) exposure ; Eagle's plans to continue to evaluate the data and conduct further research with respect to RYANODEX in the treatment of ARS ; the safety and efficacy of RYANODEX for the treatment of brain damage secondary to nerve agent exposure ; FDA approval of the use of RYANODEX for the treatment of brain damage secondary to nerve agent exposure ; Eagle's plans and ability to successfully develop and commercialize its novel fulvestrant product candidate ; Eagle's intention to conduct a subsequent clinical trial with respect to fulvestrant, including the timing of such clinical trial ; the efficacy of Eagle's fulvestrant product candidate, including the ability to achieve a greater level of estrogen receptor inhibition ; successful compliance with FDA and other governmental regulations applicable to our products and businesses ; the strength of our cash position and the ability to optimize the deployment of capital and take advantage of market opportunities ; the continued year over year growth of our revenue, EBITDA, adjusted non - GAAP earnings per share and profit margins ; the continued growth of the global biologics market and our ability to use Arsia Therapeutics (now Eagle Biologics) to enter into the biologics market and to effectively carry out our strategy in this new market ; the contribution of the RYANODEX portfolio to our growth ; the advancement of any of our other product candidates including, but not limited to, fulvestrant, pemetrexed and vasopressin, through the development process including FDA approval and the ability of any such products to have commercial success and to access significant new markets ; the success of our near - term product candidate pipeline, the Company's plans to finance and consummate the stock repurchase program, including the accelerated share repurchase (ASR) ; and the anticipated outcome of the stock repurchase program, including the ASR . All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward - looking information and statements . Such risks include, but are not limited to : whether the FDA will ultimately approve RYANODEX for the indications that we are targeting ; our relationship with our partners, including the United States Army Medical Research Institute of Chemical Defense, the market opportunity for PEMFEXY, whether we can continue to make progress with the development of fulvestrant and vasopressin, whether our bendamustine product offering will achieve the anticipated market share ; fluctuations in the trading column and market price of shares of our common stock ; difficulties or delays in manufacturing ; the availability and pricing of third party sourced products and materials ; the outcome of litigation involving any of our products or product candidates or that may have an impact on any of our products or product candidates, successful compliance with FDA and other governmental regulations applicable to product approvals, manufacturing facilities, products and/or businesses ; the strength and enforceability of our intellectual property rights or the rights of third parties ; competition from other pharmaceutical and biotechnology companies ; the timing of product launches ; the successful marketing of our products ; the risks inherent in the early stages of drug development and in conducting pre - clinical studies and clinical trials ; the possibility that the study results with respect to RYANODEX may be inaccurate or incomplete ; management's determination of alternative needs and uses of our cash resources ; the impact of general economic, industry, or political conditions in the United States or internationally ; the performance of financial markets, the fluctuation of interest rates ; and other factors that are discussed in our Annual Report on Form 10 - K for the year ended December 31 , 2018 , our Quarterly Reports on Form 10 - Q, and our other filings with the U . S . Securities and Exchange Commission . Readers are cautioned not to place undue reliance on these forward - looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward - looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non - occurrence of any events .
3 Non - GAAP Financial Performance Measures In addition to financial information prepared in accordance with U.S. GAAP, this presentation also contains adjusted non - GAAP net income, adjusted non - GAAP earnings per share and adjusted non - GAAP EBITDA attributable to the Company. The Company believes these measures provide investors and management with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect to projected information. Adjusted non - GAAP net income excludes share - based compensation expense, depreciation, amortization of acquired intangible assets, changes in fair value of contingent consideration, gain on sale of asset, debt issuance costs, severance, expense of acquired in - process research and development, asset impairment charge, legal settlement, non - cash interest expense and tax adjustments. The Company believes these non - GAAP financial measures help indicate underlying trends in the Company’s business and are important in comparing current results with prior period results and understanding projected operating performance. Non - GAAP financial measures provide the Company and its investors with an indication of the Company’s baseline performance before items that are considered by the Company not to be reflective of the Company’s ongoing results. See the following Reconciliation of GAAP to Adjusted Non - GAAP Net Income and Adjusted Non - GAAP Earnings per Share and Reconciliation of GAAP to Adjusted Non - GAAP EBITDA for explanations of the amounts excluded and included to arrive at adjusted non - GAAP net income and adjusted non - GAAP earnings per share amounts for the twelve months ended December 31, 2018, 2017, 2016 and 2015, and adjusted non - GAAP EBITDA amounts, for the twelve months ended September 30, 2019 and December 31, 2018, 2017, 2016 and 2015, respectively. These adjusted measures are non - GAAP and should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. The Company strongly encourages investors to review its consolidated financial statements and publicly - filed reports in their entirety and cautions investors that the non - GAAP measures used by the Company may differ from similar measures used by other companies, even when similar terms are used to identify such measures.
4 The Eagle Story: Building from Our Successes Two significant initial successes : bendamustine and RYANODEX ® From 2015 - YTD2019: generated approximately $250 mm in cash flow from operations * creating substantial profitability Efficient business model and successful cash re - investment: x Share repurchase: bought back $169 mm , or 17%, vs. $110 mm issued; only 13.7 million basic shares outstanding x Invested 20%+ of revenue in non - GAAP Research & Development Healthy balance sheet : no net debt and ability to deploy capital for in - licensing/acquisitions Significant near - term pipeline : focus on best - in - class oncology and critical care (including medical countermeasures against terrorism) RYANODEX for brain damage secondary to Nerve Agent (NA) Exposure, Acute Radiation Syndrome (ARS) and Exertional Heat Stroke (EHS) Fulvestrant, PEMFEXY™ Anticipate important news flow over the next six months *Excludes receivables build
5 Built a Highly Profitable Company Since Our IPO; Durable Cash Flow Generation; No Net Debt $45 $50 $38 $0 $7 $64 $96 $71 $5 $69 $71 $65 $0.41 $2.79 $4.34 $3.87 2015 2016 2017 2018 (US$MM, except per share data) Milestone & Licensing Revenues EBITDA Cash Flow From Operations Non-GAAP EPS
6 Recent New Highlights Reached settlement agreement with Eli Lilly for Eagle’s PEMFEXY (12/13/19) • Allows for initial entry of PEMFEXY, approx . three week supply of current ALIMTA® utilization on February 1, 2022 and a subsequent uncapped entry on April 1, 2022 • Based on IMS data, the 500mg ALIMTA U.S. market is approximately 360,000 vials/ yr (approx. $1b/ yr ) Granted orphan drug designation for RYANODEX for the treatment of organophosphate* exposure (12/13/19) Completed enrollment in fulvestrant pilot study (12/12/19) • Results will inform design of pivotal trial for novel product for estrogen receptor positive breast cancer patients Announced our intention to refile RYANODEX for exertional heat stroke shortly (8K filed on 12/10/19) *a class of chemicals that includes potent pesticides and chemical weapons, known as nerve agents.
7 The Eagle Story: Building from Our Successes Our innovative products make a significant difference in patient care : • Improve the treatment of underlying conditions • New indications for existing drugs • Address urgent problems for patient populations Our marketed products and significant near - term pipeline : • BENDEKA ® : • Meaningful innovation in cancer care for Non - Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL); dosing in 10 minutes • RYANODEX: • Malignant hyperthermia (MH) and EHS (returned to 2019 Hajj) • Brain damage secondary to NA Exposure and ARS: protecting our military around the globe and potentially U.S. civilians as well • Undisclosed indications • EA - 111: developing the next ryanodine receptor inhibitor for acute care administration • Fulvestrant: potential for better outcomes in the treatment of breast cancer • PEMFEXY: innovate ready - to - dilute (RTD) formulation eliminating reconstitution steps Our priority: reinvest our R&D dollars to build for future success
Oncology Portfolio: Targeting Best - in - Class Solutions
9 Oncology Assets: Building from Our Successes Bendamustine: highly successful franchise • Established royalty revenue beyond 2025 • TREANDA generics: not expected before Dec 2022 • Long - term cash flow stream • 15 Orange Book listed patents through 2031 and unique J - code • BENDEKA royalty increase: from 25% to 30% on 10/1/19 and then increases by 1 percentage point on each anniversary thereafter until it reaches 32% PEMFEXY : reached settlement agreement with Lilly on 12/13/2019 • Allows for initial entry of PEMFEXY of approx. three week supply of current ALIMTA® utilization on February 1, 2022 and a subsequent uncapped entry on April 1, 2022 • Based on IMS data, the 500mg ALIMTA U.S. market is approximately 360,000 vials/ yr (approx. $1b/ yr ) • Generic entrants blocked until 05/24/22 • FDA granted tentative approval of RTD PEMFEXY on Oct. 27, 2017
10 Oncology Assets: Building from Our Successes Fulvestrant: Breast Cancer Overview • Multi - billion - dollar worldwide market opportunity targeting patients across estrogen receptor positive (ER+) breast cancer • 2018 sales of branded product 1 : • U.S. $537 mm • WW: $1+ B 1 2018 Sales of AstraZeneca’s Faslodex
11 • Approximately 75% of breast cancers are ER+ • Fulvestrant is a selective estrogen receptor (ER) degrader (SERD) • Acts as an antagonist at the ER • Does not exhibit any known agonist activity • Fulvestrant acts in ER+ breast cancer by binding competitively to the ER • Inhibits estrogen - stimulated cell division • Reduces the number of ERs through degradation and downregulation Fulvestrant Opportunity: Potential to Change Treatment of ER+ Breast Cancer
12 Fulvestrant Opportunity: Potential to Change Treatment of ER+ Breast Cancer • Eagle’s original fulvestrant formulation studied in 2018 clinical trial in 600 healthy post - menopausal (PM) women over 140 days • 300 subjects received the branded product FASLODEX® • 300 subjects received Eagle’s formulation • Eagle’s research on the delivery of fulvestrant resulting from the Company’s 2018 clinical trial has led to the discovery of significant areas of improvement of existing therapies • Through Eagle’s proprietary research, the Company has developed improved delivery technology that may enhance blocking of the proliferative activity of estrogen and downregulating the estrogen receptor
13 Fulvestrant Development Progress • Pilot study enrollment in healthy PM women is complete • Based on the results of the pilot study in healthy PM women, a pivotal study will commence in PM ER+ cancer patients • Pivotal study intends to evaluate residual ER availability • Hope to complete the pivotal study within 12 months after initiation of enrollment, which we expect to commence in 2020 • Results of the pilot study will strongly inform the final design of the pivotal trial • Anticipate novel product could enter the market by 1 st half of 2022
Critical Care (including medical countermeasures for terrorism) Targeting Best - in - Class Solutions
15 RYANODEX: Building from Our Successes RYANODEX today : Approved for malignant hyperthermia (MH): a life - saving drug • Innovative formulation of dantrolene sodium allowing for fast and efficient treatment • Approved July 2014; launched August 2014 • Eight U.S. patents issued to date, expiring between 2022 and 2025 Multiple exciting new indications* underway: • Treatments for brain damage secondary to NA Exposure, ARS, EHS • Two undisclosed indications that we expect to announce soon EA - 111: new chemical entity and administration method *not yet approved by U.S. FDA
16 RYANODEX: Building a Successful Franchise RYANODEX Exertional Heat Stroke (EHS) Nerve Agent (NA) Exposure MH (Approved) Undisclosed indications Acute Radiation Syndrome (ARS) New Indications Under Development
17 Understanding Medical Countermeasures 1 (MCMs) • Medical Countermeasures : FDA - regulated products (biologics, drugs, devices) that may be used in the event of a potential public health emergency stemming from a terrorist attack with a biological, chemical, or radiological/nuclear material, or a naturally occurring emerging disease. • MCMs can be used to: Diagnose, prevent, protect from, or treat conditions associated with chemical, biological, radiological, or nuclear (CBRN) threats, or emerging infectious diseases. 1 U.S. Food and Drug Administration Medical Countermeasures Initiative ( MCMi ) dated 12/19/18
18 Overview of Strategic National Stockpile • Designed to supplement and resupply state and local inventories of medicines and supplies during emergencies severe enough to exhaust local supplies. 1 • HHS and the CDC look at multiple factors, including the medical vulnerability of the U.S. population (and of at - risk populations such as children and other vulnerable populations), current biological/chemical threats, the availability of medicines and medical supplies, and the ease of disseminating specific medicines. 2 1 CDC. “Strategic National Stockpile (SNS)” webpage. Available at www.cdc.gov/phpr/stockpile/stockpile.htm . 2 ASTHO. The Strategic National Stockpile: From Concept to Achievement. August 2010. Available at http://www.astho.org/Programs/Preparedness/Strategic - National - Stockpile/The - Strategic - National - Stockpile -- From - Concept - to - Achiev ement/ .
19 RYANODEX: Treatment of Brain Damage Secondary to NA Exposure Addresses Global Concern About Potential for an NA Attack Public Health Initiatives Federal Agencies, including the Departments of Homeland Security and Health and Human Services, have issued multiple documents highlighting the risks of exposure to these extremely toxic chemical warfare agents Agreement w/ US Army Q4 2018: Eagle entered into an agreement with the United States Army Medical Research Institute of Chemical Defense (USAMRICD) to evaluate the neuroprotective effects of RYANODEX in a well - established NA model Statistically Significant Results Q2 2019: Results of the study conducted by USAMRICD demonstrated a statistically significant lower level of brain damage secondary to NA exposure in RYANODEX - treated animals, compared to controls (p value: ≤0.04) If approved, RYANODEX would be a first - of - its - kind medical countermeasure for the treatment of brain damage secondary to NA exposure
20 Promising Results for a Critical Product: NA Countermeasures Topline Study with U.S. Military • Statistically significant neuroprotective effects of RYANODEX in critical cortical areas of the brain • In six areas of the brain examined, animals treated with RYANODEX experienced a lower level of brain damage Histopathology of Frontal Cortex, comparing RYANODEX - treated animals (left) and control animals (right) Ryanodex (30 mg/kg), 60 minutes post - seizure onset. Day 1, 20x objective magnification, H&E. Frontal cortex with grade 1 neuronal necrosis. Necrotic neurons denoted with black arrows. Vehicle Control (15 mg/kg), 60 minutes post - seizure onset. Day 1, 20x objective magnification, H&E. Frontal cortex with grade 4 neuronal necrosis. Necrotic neurons denoted with black arrows. Unaffected neurons denoted with white arrows.
21 RYANODEX: Animal Study for Acute Radiation Syndrome (ARS) Study Objective Evaluate efficacy of IV administration of RYANODEX to prevent or mitigate ARS in a total body irradiated C57BL/6 male mouse hematopoietic model Positive Animal Testing Results Positive results of a proof - of - concept (POC) study in a Total - Body Radiation Animal Model RYANODEX treatment group had overall less mortality post - treatment than non - treated animals with ARS Indication is likely to be developed under FDA’s “Animal Rule” Further indication exploration Exploring investigational indication for RYANODEX for treatment of hematopoietic syndrome in individuals exposed to high doses of radiation, such as nuclear power plant leakage or nuclear weapons Additional research is ongoing to evaluate hematopoietic syndrome in certain cancer patients undergoing radiation therapy
22 RYANODEX: Exertional Heat Stroke (EHS) Company returned to 2019 Hajj and enrolled additional EHS patients in its controlled clinical study Evaluate efficacy and safety of Ryanodex in addition to standard of care (body cooling) in patients with EHS Currently there is no drug treatment for EHS. Efficient body cooling is not always available and is randomly administered. If approved, Ryanodex would be the first and only drug treatment for this rare and life - threatening condition. Completed two clinical trials – have collected a substantial amount of data to meet FDA expectations for regulatory review Announced our intention to refile RYANODEX for EHS Study Objective Unmet medical needs Positive Results
23 EA - 111 Development Is Under Way • Developed new chemical entities (NCE) related to dantrolene • Significant benefits of an intramuscular (IM) formulation • EA - 111 would allow for easier and more rapid administration in emergency situations (military and civilian) • Enables point - of - care administration to patients in need • Eliminates IV - infusion • Anticipate 5 - year NCE regulatory exclusivity post - FDA approval
24 Vasopressin and Future In - Licensing Opportunities Vasopressin • Indicated to increase blood pressure in adults with vasodilatory shock ( eg post - cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamine • Generic version of Endo International plc’s original VASOSTRICT® • $506 million in brand sales 1 LTM • Eagle is first - to - file an ANDA referencing VASOSTRICT; submission accepted for filing by FDA April 2019 Supplement organic growth through in - licensing and acquisitions • Strong balance sheet provides opportunity for external business development 1 http://investor.endo.com/news - releases/news - release - details/endo - reports - third - quarter - 2019 - financial - results; http://investor.endo.com/news - releases/news - release - details/endo - reports - fourth - quarter - and - full - year - 2018 - financial - results
25 Financial Highlights • L TM EBITDA $60.4 mm LTM Cash Flow from Operations, excluding A/R shifts $63.7 mm Cash $117.2 mm A/R $44.8 mm • Share Repurchase Plan as of 12/13/19 • $172 mm repurchased since August 2016, including $50 mm ASR executed 10/30/18 • 2.9 mm shares repurchased since August 2016 • 1.9 mm shares repurchased through OMR • 1.0 mm shares repurchased through ASR • $150 mm new authorization (including $50 mm ASR) approved by the Board October 2018 • $82 mm remaining • 13.7 mm basic shares outstanding at 10/31/19 • $150 mm credit facility November 2019 • $40 mm term loan • $110 mm revolver As of 9/30/19
26 Thank you December 2019 Our Passion and Commitment to Patient Care: Building for Continued Success
27 APPENDIX
28 Reconciliation of GAAP to Adjusted Non - GAAP Net Income Explanation of Adjustments: 1) Amortization of intangible assets for Ryanodex and Docetaxel 2) Amortization of intangible assets for Eagle Biologics 3) Gain on divestiture of diclofenac - misoprostol 4) Changes in the fair value of contingent consideration (Docetaxel and Eagle Biologics) 5) Reflects the estimated tax effect of the pretax adjustments, $3.4 million of tax expense from U.S. tax reform which is reflected in 2017 and the reversal of a tax valuation allowance in 2016 2018 2017 2016 2015 Net income - GAAP 31,903$ 51,943$ 81,453$ 2,571$ Adjustments: Cost of product revenues: Amortization of acquired intangible assets (1) 895 1,194 746 - Research and development: Share-based compensation expense 4,014 3,942 2,914 1,271 Depreciation 470 74 - - Expense of acquired in-process research & development 1,700 1,000 - - Severance 466 - - - Selling, general and administrative: Share-based compensation expense 15,068 11,487 6,853 2,780 Amortization of acquired intangible assets (2) 1,620 1,620 203 - Depreciation 685 858 640 112 Debt issuance costs - 286 - - Severance - 268 - - Other: Gain on sale of asset (3) - - (1,750) - Non-cash interest expense 376 238 8 - Change in fair value of contingent consideration (4) (763) (7,378) 957 - Asset impairment charge 2,704 7,235 - - Restructuring charge 7,911 - - - Legal settlement - 1,650 - - Tax effect of the non-GAAP adjustments (5) (7,894) (5,368) (46,103) - Adjusted non-GAAP net income 59,155$ 69,049$ 45,921$ 6,734$ Adjusted non-GAAP earnings per share Basic 4.01$ 4.57$ 2.96$ 0.44$ Diluted 3.87$ 4.34$ 2.79$ 0.41$ Weighted number of common shares outstanding: Basic 14,768,625 15,102,890 15,533,681 15,250,154 Diluted 15,278,651 15,908,211 16,434,104 16,253,781 Twelve Months Ended December 31,
29 Reconciliation of GAAP to Adjusted Non - GAAP EBITDA (000’s) Twelve Months Ended September 30, Twelve Months Ended December 31, 2019 2018 2017 2016 2015 Net income - GAAP $ 25,898 $ 31,903 $ 51,943 $ 81,453 $ 2,571 Add back: Interest expense (income), net 774 2,579 1,045 (76) (14) Income tax provision 7,976 2,135 21,002 (28,026) 3 Depreciation and amortization 3,451 3,670 3,746 1,589 112 Stock - based compensation 21,385 19,082 15,429 9,768 4,051 Change in fair value of contingent consideration - (763) (7,378) 957 - Debt issuance costs - - 286 - - Asset impairment charge - 2,704 7,235 - - Gain on sale of asset - - - (1,750) - Expense of acquired in - process research & development 500 1,700 1,000 - - Severance - 466 268 - - Restructuring charge 432 7,911 - - - Legal settlement - 1,650 Adjusted Non - GAAP EBITDA $ 60,416 $ 71,387 $ 96,226 $ 63,915 $ 6,723